Mount Tam Biotechnologies Announces Collaboration To Study Potential In Parkinson’s Disease

NOVATO, CA--(Marketwired - July 27, 2017) - Mount Tam Biotechnologies, Inc. (“Mount Tam”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR modulators, is pleased to announce that it has entered into an Agreement with the University of Chile and the Laboratory of Claudio Hetz, Ph.D., to explore the potential of Mount Tam’s novel compounds in Parkinson’s disease. Under this Agreement, Dr. Hetz and his colleagues will use their extensive experience and capabilities in testing investigational drug candidates in animal models of neurodegenerative diseases to better understand the potential for selective mTORC1 inhibitors in Parkinson’s Disease.

Dr. Hetz is Professor and Co-Director of the Biomedical Neuroscience Institute at the Faculty of Medicine, University of Chile and is an Adjunct Professor at the Harvard School of Public Health and Adjunct Professor at the Buck Institute for Research on Aging. He is also Director of the Neurounion Biomedical Foundation in Santiago Chile. Dr. Hetz has published over 150 scientific publications, books, and book chapters and his laboratory has received grants from the Michael J. Fox Foundation, the Muscular Dystrophy Association and the ALS Therapy Alliance, amongst others.

“We are very excited to collaborate with this world renowned laboratory to explore how we can address the very real unmet need in Parkinson’s disease. We believe that a selective mTORC1 inhibitor has the potential to meaningfully improve patients’ symptoms and quality of life, and this is a critical step to advance in this direction,” said Mount Tam’s Chief Scientific Officer, Tim Powers, Ph.D.

According to Dr. Hetz, “We are very pleased to enter into this collaboration as we believe that novel mTOR modulators have potential to improve outcomes in Parkinson’s disease as well as in a range of neurodegenerative disorders.”

About Mount Tam Biotechnologies, Inc.

Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. Mount Tam believes it has an industry leadership position in developing therapeutic products which address aberrations in the mTOR pathway, and is confident that both TAM-01 and TAM-03 are significantly differentiated from currently marketed rapalogs and have the potential to bring significant benefits to patients.

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The licensed assets are highly target-specific polyketides. Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has largely completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.

For more information visit www.MountTamBiotech.com

Forward-Looking Statements:

The information disclosed in this press release is made as of the date hereof and reflects Mount Tam’s most current assessment of its historical position and financial performance. Actual results may differ from those contained herein due to factors outside of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.

These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as “scheduled (future sense)”, “intend(s)”, “plan(s)”, “expect(s)”, “believe(s)”, “will”, “estimate(s)”, “anticipate(s)”, “expect(s)”, “may”, “would”, “could” or “should” or, in each case, the negative thereof, other variations thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of any such application. Although Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking statements for subsequent events.